|Podcasts|October 1, 2020
Episode 66: New Approach to Antithrombotics
Author(s)Elaine Quilici
Dr. Neil Hayward, CEO and founder of eXlthera, is here to discuss his company, which is developing Factor XI inhibitor antithrombotics that are attacking blood clots from a new angle and are giving patients new hope.
Advertisement
Dr. Neil Hayward, CEO and founder of eXlthera, is here to discuss his company, which is developing Factor XI inhibitor antithrombotics that are attacking blood clots from a new angle and are giving patients new hope.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Releases Open Letter Warning of Potential Safety Risks for Compounded Tirzepatide Plus Vitamin B12
2
What is Shadow AI and How is it Impacting Pharma Companies?
3
How Does FDA's Single Trial Decision Change The Risk Calculus for Sponsors
4
Agentic AI and the Future of Commercial Excellence in Life Sciences
5